Immune Checkpoint PD-1/PD-L1: Is There Life Beyond Antibodies?

Konstantinidou, Markella; Zarganes-Tzitzikas, Tryfon; Magiera-Mularz, Katarzyna; Holak, Tad A.; Domling, Alexander

doi:10.1002/anie.201710407

Item

ITEM ACTIONSEXPORT

Add to Basket

Local TagsRelease HistoryDetailsSummary

Released

Journal Article

Immune Checkpoint PD-1/PD-L1: Is There Life Beyond Antibodies?

MPS-Authors

/persons/resource/persons78123

Holak, Tad A.
Holak, Tad / NMR Spectroscopy, Max Planck Institute of Biochemistry, Max Planck Society;

External Resource

No external resources are shared

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

Fulltext (public)

There are no public fulltexts stored in PuRe

Supplementary Material (public)

There is no public supplementary material available

Citation

Konstantinidou, M., Zarganes-Tzitzikas, T., Magiera-Mularz, K., Holak, T. A., & Domling, A. (2018). Immune Checkpoint PD-1/PD-L1: Is There Life Beyond Antibodies? Angewandte Chemie International Edition, 57(18), 4840-4848. doi:10.1002/anie.201710407.

Cite as: https://hdl.handle.net/21.11116/0000-0002-C75B-8

Abstract

The PD-1/PD-L1 interaction has emerged as a significant target in cancer immunotherapy. Current medications include monoclonal antibodies, which have shown impressive clinical results in the treatment of several types of tumors. The cocrystal structure of human PD-1 and PD-L1 is expected to be a valuable starting point for the design of novel inhibitors, along with the recent crystal structures with monoclonal antibodies, small molecules, and macrocycles.